Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Pioneering exosome platform with a differentiated approach. </li><li>NurExone is built around a proprietary platform that addresses a profound medical need.</li><li>Lead asset ExoPTEN targets multi-billion-dollar markets in central nervous system (CNS) injury—including acute spinal cord injury (SCI) and optic nerve damage—using naturally targeting exosomes loaded with PTEN-silencing siRNA via a dual-action mechanism. </li></ul>

Pioneering exosome platform with a differentiated approach. NurExone is built around a proprietary platform that addresses a profound medical need.Lead asset ExoPTEN targets multi-billion-dollar markets in central nervous system (CNS) injury—including acute spinal cord injury (SCI) and optic nerve damage—using naturally targeting exosomes loaded with PTEN-silencing siRNA via a dual-action mechanism. 

NRX: Initiating Coverage; A Novel Exosome Platform at the Frontier of CNS Regeneration

<ul><li>Differentiated, minimally invasive technology platform. </li><li>NurExone’s lead product candidate, ExoPTEN, uses exosomes loaded with siRNA to promote neural regeneration after central nervous system trauma such acute spinal cord injury or optic nerve injury.</li><li>Unlike competing approaches (e.g., stem cell transplants or electrical stimulation), ExoPTEN is cell-free, crosses the blood-brain barrier naturally, and can be administered with minimal invasiveness, all of which bring a significant clinical and operational advantage.</li></ul>

Differentiated, minimally invasive technology platform. NurExone’s lead product candidate, ExoPTEN, uses exosomes loaded with siRNA to promote neural regeneration after central nervous system trauma such acute spinal cord injury or optic nerve injury.Unlike competing approaches (e.g., stem cell transplants or electrical stimulation), ExoPTEN is cell-free, crosses the blood-brain barrier naturally, and can be administered with minimal invasiveness, all of which bring a significant clinical and operational advantage.

NRX: From Preclinical Promise to Clinical Execution

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company annual financial results that continued to show management discipline and an improved cash balance.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company annual financial results that continued to show management discipline and an improved cash balance.

NRXBF: Annual Results Show Company on Track

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company announced clinical tests that showed the company's proprietary exosomes "significantly reduced inflammation" in cell, both untreated and those treated with a commercially available product.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced clinical tests that showed the company's proprietary exosomes "significantly reduced inflammation" in cell, both untreated and those treated with a commercially available product.

NRXBF: Treatment Shows Inflammation Reduction

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

Israel

NurExone Biologic Inc. operates as a biotech company. The Company develops novel, biologic, and minimal-invasive treatment for spinal cord injury and traumatic brain injury. NurExone Biologic serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Nurexone Biologic (NRXBF US)

NRX: Initiating Coverage; A Novel Exosome Platform at the Frontier of CNS Regeneration

Pioneering exosome platform with a differentiated approach. NurExone is built around a proprietary platform that addresses a profound medical need.

Water Tower Research

NRX: From Preclinical Promise to Clinical Execution

NurExone’s lead product candidate, ExoPTEN, uses exosomes loaded with siRNA to promote neural regeneration after central nervous system trauma such...

Water Tower Research

NRXBF: Annual Results Show Company on Track

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Treatment Shows Inflammation Reduction

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)